Photocure ASA: Results for the first quarter of 2022
Oslo, Norway, 11 May 2022: Photocure ASA (OSE:PHO) today reported Hexvix[®]/Cysview[®] revenues of NOK 81.4 million in the first quarter of 2022 (Q1 2021: NOK 81.6 million), following the recent Covid-19 surge and its impact on hospital access and staffing, which affected commercial operations in January and February. Access and procedure volumes experienced a recovery in March, and the Company expects installations of Blue Light Cystoscopy (BLC) towers in the U.S. to accelerate during the second half of 2022 once Karl Storz’s new high-definition system is launched.“In the first quarter of